Q1 Earnings Forecast for Zai Lab Issued By Leerink Partnrs

Zai Lab Limited (NASDAQ:ZLAB) – Stock analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for Zai Lab in a report released on Thursday, February 20th. Leerink Partnrs analyst J. Chang expects that the company will post earnings per share of ($0.51) for the quarter. The consensus estimate for Zai Lab’s current full-year earnings is ($2.58) per share. Leerink Partnrs also issued estimates for Zai Lab’s Q1 2025 earnings at ($0.51) EPS, Q2 2025 earnings at ($0.44) EPS, Q2 2025 earnings at ($0.44) EPS, Q3 2025 earnings at ($0.37) EPS, Q3 2025 earnings at ($0.37) EPS, Q4 2025 earnings at ($0.30) EPS and Q4 2025 earnings at ($0.30) EPS.

Separately, Cantor Fitzgerald upgraded shares of Zai Lab to a “strong-buy” rating in a report on Wednesday, February 5th.

Zai Lab Trading Up 9.0 %

Shares of NASDAQ:ZLAB opened at $33.78 on Monday. Zai Lab has a 12 month low of $13.48 and a 12 month high of $36.60. The stock has a market cap of $3.70 billion, a P/E ratio of -12.19 and a beta of 1.02. The company has a 50 day moving average of $26.90 and a 200 day moving average of $25.33.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. DekaBank Deutsche Girozentrale lifted its position in shares of Zai Lab by 22.2% during the third quarter. DekaBank Deutsche Girozentrale now owns 36,648 shares of the company’s stock worth $899,000 after purchasing an additional 6,648 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of Zai Lab by 58.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,559 shares of the company’s stock worth $231,000 after buying an additional 3,514 shares during the period. Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Zai Lab by 26.2% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 604,153 shares of the company’s stock worth $14,584,000 after purchasing an additional 125,532 shares in the last quarter. Algert Global LLC purchased a new stake in Zai Lab in the 3rd quarter valued at $1,666,000. Finally, Daiwa Securities Group Inc. increased its position in shares of Zai Lab by 4,851.8% during the 3rd quarter. Daiwa Securities Group Inc. now owns 9,557 shares of the company’s stock worth $231,000 after purchasing an additional 9,364 shares during the last quarter. 41.65% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, insider Rafael Amado sold 7,583 shares of the firm’s stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $26.28, for a total value of $199,281.24. Following the completion of the transaction, the insider now directly owns 33,834 shares of the company’s stock, valued at approximately $889,157.52. This trade represents a 18.31 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 13.88% of the stock is currently owned by insiders.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.